Results 151 to 160 of about 10,425 (248)

Neurology — to be or not to be of the cannabis-based medicine?

Neurologia i Neurochirurgia Polska, 2022
openaire   +3 more sources

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review. [PDF]

Clin Drug Investig
Cooling S, Bonomo YA, Castle D, Hallinan CM.   +3 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Nitrogen source and solution strength modulate cannabinoid and antioxidant profiles in medicinal cannabis grown in a deep-water culture system. [PDF]

Sci Rep
Hasanalizade M, Samadi A, Alirezalu A, Noruzi P.   +3 more
europepmc   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

Cannabinoid CB1 allosteric ligands suppress inflammatory pain in male mice without tolerance, motor impairment, memory deficits or respiratory depression

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Positive allosteric modulators (PAMs) engage sites distinct from the orthosteric CB1 cannabinoid receptor binding site. GAT211, a racemic ligand, contains GAT228 (R) and GAT229 (S) enantiomers. Whether enantiomer‐mediated differences in allosteric activation or positive allosteric modulation translate into differences in
Ifeoluwa D. Solomon, Sumanta Garai, Ganesh A. Thakur, Andrea G. Hohmann   +3 more
wiley   +1 more source

Genotype and chemotype insights of high-THC medicinal Cannabis sativa L.: the role of SSR markers in the identification of cultivars. [PDF]

J Cannabis Res
Gomes AP, Vicente S, Rosa J, Vinhas I, da Costa AM, Sassano M, Rodrigues LM, Rijo P, Trindade H, Céu Costa MD.   +9 more
europepmc   +1 more source

Parents With Substance Use Disorder in the Holding Tight Treatment System: Intervention Effectiveness and Moderating Effects

Child &Family Social Work, EarlyView.
ABSTRACT Parents with substance use disorder have multiple risks affecting their parenting. Mental health problems and adverse childhood experiences (ACEs) with problems in emotion regulation and adult attachment insecurity may impair the early interaction with the infant.
Saara J. Salo, Marjo Flykt, Yan Li, Mirjam Kalland, Marjukka Pajulo   +4 more
wiley   +1 more source

Consumer perspectives of accessing medicinal cannabis treatment from cannabis clinics versus generalist health settings in Australia. [PDF]

J Cannabis Res
Lintzeris N, Arnold JC, McGregor IS, Mills L.   +3 more
europepmc   +1 more source